Stockscreener 앱 받기
0.19%
시장 영업 전:
전일 마감가:
$25.80
열려 있는:
$25.835
하루 거래량:
51.03M
Relative Volume:
0.76
시가총액:
$146.98B
수익:
$62.79B
순이익/손실:
$9.84B
주가수익비율:
15.07
EPS:
1.7156
순현금흐름:
$10.38B
1주 성능:
-0.69%
1개월 성능:
-0.08%
6개월 성능:
+4.07%
1년 성능:
+1.89%
1일 변동 폭
$25.72
$26.04
1주일 범위
$25.13
$26.19
52주 변동 폭
$20.91
$27.69
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.85 | 146.69B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer’s Hold Rating: Navigating Loss of Exclusivity and Flat Growth Prospects - TipRanks
47,996 Shares in Pfizer Inc. $PFE Acquired by MASTERINVEST Kapitalanlage GmbH - MarketBeat
Marex Group plc Purchases Shares of 65,461 Pfizer Inc. $PFE - MarketBeat
Will Dogecoin Reach $1 By the End of the Year? - The Motley Fool
Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next - ts2.tech
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks - ts2.tech
Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks
Orion Porfolio Solutions LLC Has $17.19 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025) - ts2.tech
Evergreen Capital Management LLC Purchases 63,611 Shares of Pfizer Inc. $PFE - MarketBeat
Forget Teladoc and Buy This Healthcare Stock Instead - Yahoo Finance
Bellevue Group AG Reduces Holdings in Pfizer Inc. $PFE - MarketBeat
Banque Transatlantique SA Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open - ts2.tech
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 - marketscreener.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 - Investing.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 By Investing.com - Investing.com Canada
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. - The Globe and Mail
Pfizer Declares First-Quarter 2026 Dividend - Business Wire
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring? - simplywall.st
Treasurer of the State of North Carolina Purchases 520,580 Shares of Pfizer Inc. $PFE - MarketBeat
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial - Reuters
NewEdge Advisors LLC Acquires 97,789 Shares of Pfizer Inc. $PFE - MarketBeat
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
CIBC Asset Management Inc Trims Stock Position in Pfizer Inc. $PFE - MarketBeat
Camber Capital Management LP Has $36.36 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. - Britannica
Elevance Health Adds Former Pfizer GC To Its Board - Law360
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield - ts2.tech
Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience - Healthcare Dive
Pfizer plans job cuts in Switzerland to reduce expenses - Yahoo Finance
Down 50%, should you buy the dip on Pfizer? - MSN
Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study - Finviz
Pfizer Inc. $PFE Shares Sold by Schwerin Boyle Capital Management Inc. - MarketBeat
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
Will Obesity Bet and TUKYSA Data Shift Pfizer’s (PFE) Post-COVID Growth Narrative? - simplywall.st
Pfizer Inc. $PFE Shares Sold by Marshall Wace LLP - MarketBeat
Pfizer Inc. $PFE Shares Sold by Becker Capital Management Inc. - MarketBeat
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating - Yahoo Finance
Pfizer Plans Workforce Reduction in Switzerland - marketscreener.com
Pfizer Could Claim Tukysa First-Line HER2+ Metastatic Breast Cancer Indication - Citeline News & Insights
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Pfizer to cut hundreds of jobs in Switzerland by year-end - Investing.com India
Pfizer stock gets Outperform rating from BMO as tucatinib shows promise - Investing.com
Former Pfizer physician challenges RIF, OWBPA disclosures in court - HRD America
Pfizer Plans to Cut 200+ Employees in Switzerland: Wire - AASTOCKS.com
Pfizer is shedding hundreds of jobs in Switzerland (PFE:NYSE) - Seeking Alpha
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.28%
0.11%
자본화:
|
볼륨(24시간):